AI assistant
Schott Pharma Investor Presentation 2026
6514_ip_2026-05-12_3da6bf0e-0df6-426d-9b41-30cdef4010a0.pdf
Investor Presentation
Open in viewerOpens in your device viewer
SCHOTT PHARMA
H1 2026 Results Presentation
Christian Mias, CEO | Reinhard Mayer, CFO
The fiscal year 2026 runs from October 2025 to September 2026.
© SCHOTT Pharma
Disclaimer
This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.
This publication has been prepared by SCHOTT Pharma AG & Co. KGaA. It may contain statements which address such key issues as strategy, future financial results, events, competitive positions and product developments. Such forward-looking statements are subject to a number of risks, uncertainties and other factors, including, but not limited to those described in SCHOTT Pharma's disclosures, in particular in the chapter "Risks" in SCHOTT Pharma's annual report. Should one or more of these risks, uncertainties and other factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performances or achievements of SCHOTT Pharma may vary materially from those described in the relevant forward-looking statements.
These statements may be identified by words such as "expect," "want," "anticipate," "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. SCHOTT Pharma neither intends, nor assumes any obligation, to update or revise its forward-looking statements regularly in light of developments which differ from those anticipated. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.
Our financial reports, presentations, press releases and ad-hoc releases may include alternative financial metrics. These metrics are not defined in the IFRS (International Financial Reporting Standards). SCHOTT Pharma's net assets, financial position and results of operations should not be assessed solely on the basis of these alternative financial metrics. Under no circumstances do they replace the performance indicators presented in the consolidated financial statements and calculated in accordance with the IFRS. The calculation of alternative financial metrics may vary from company to company despite the use of the same terminology. Further information regarding the alternative financial metrics used at SCHOTT Pharma can be found on our web site (https://www.schott-pharma.com/investor-relations).
The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.
Due to rounding, individual numbers presented throughout this, and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.
For technical reasons, there may be differences in formatting between the accounting records appearing in this document and those published pursuant to legal requirements.
SCHOTT Pharma
Professional background in a nutshell
Christian Mias
CEO SCHOTT Pharma
since May 1, 2026
Ph.D. in Industrial Engineering,
studied in Berlin and Tokyo
Professional career started at Siemens AG,
focusing on M&A and project management
More than 18 years with SCHOTT,
mainly in international leadership positions in Brazil,
the US, and Germany
Led Tubing plant in Rio de Janeiro;
restructured American plants of Flat Glass
Headed Lighting & Imaging;
most recently in charge of Electronic Packaging, driving global
performance, strategic development, and cultural change
© SCHOTT Pharma
Business Update
Christian Mias, CEO
© SCHOTT Pharma
Ongoing stable development H1 2026
EUR 488m
Revenue
(+2.3 % at constant currencies)
EUR 130m
EBITDA
(margin of 26.6 %)
56%
HVS revenue share
(+1 percentage point year-over-year)
5 © SCHOTT Pharma
Expansion of HVS drives profitable growth
Value drivers
Share of revenue with HVS
Strategic importance of HVS
HVS drive growth and margin expansion.
Strategy focuses on addressing pharma trends with innovation.
Continuous increase of HVS revenue share reflects success.
© SCHOTT Pharma
Further strengthening the HVS portfolio with innovations
Latest example: cartriQ® Biopure mitigates systemic risks in packaging of biologics
© SCHOTT Pharma
O
Financial Update
Reinhard Mayer, CFO
© SCHOTT Pharma
DCS grows dynamically, DDS with temporary headwinds
Revenue¹
EURm
¹ Segment split excluding consolidation effects, cc = at constant currencies
© SCHOTT Pharma
Key developments
Revenue in H1 2026 slightly above prior-year level, reflecting a resilient demand environment.
Drug Containment Solutions (DCS) delivered strong growth, driven by continued high demand for sterile solutions and specialty vials.
Revenues in Drug Delivery Systems (DDS) declined year-on-year due to lower polymer syringe demand.
O
Strong margin performance in DCS offsets temporary headwinds in DDS
EBITDA¹ and margin
EURm
¹ Segment split excluding consolidation effects, cc = at constant currencies
Key developments
EBITDA in H1 2026 remained at a high level, while the EBITDA margin slightly decreased year-on-year due to temporary effects.
DCS: EBITDA increased disproportionately, driven by strong volume growth and a favorable product mix.
DDS: EBITDA down due to lower utilization and a one-off inventory impairment. Adjusted for the impairment effect, profitability would have been almost on prior-year level, demonstrating the underlying strength of the business.
10 © SCHOTT Pharma
Further down the P&L…
| EURm | H1 2026 | H1 2025 | Δ yoy |
|---|---|---|---|
| EBIT | 86.5 | 92.9 | -6.9% |
| Financial result | -4.1 | -6.5 | -36.1% |
| EBT | 82.4 | 86.4 | -4.7% |
| Income tax expense | -17.9 | -18.3 | -2.2% |
| Profit for the period | 64.4 | 68.1 | -5.4% |
| EPS (EUR) | 0.43 | 0.45 | -5.4% |
Key developments
EBIT -6.9% mainly due to the one-off inventory impairment and higher depreciation as a result of growth investments.
Financial result improved because of lower interest expenses following optimized financing structure.
Income taxes slightly down to EUR 18m, representing an effective tax rate of 21.8%.
Overall, net income decreased 5.4% yoy to EUR 64.4m and earnings per share (EPS) amounted to EUR 0.43.
11 © SCHOTT Pharma
O
Significantly higher cash generation driven by working capital improvements
Free cash flow
EURm
1 Op. CF = Cash flow from operating activities; 2 Inv. CF = Cash flow from ongoing investing activities
Key developments
Operating cash flow benefited from focused working capital management, despite inventory build-up to support future growth.
Cash flow from ongoing investing activities in line with prior year's level at around EUR 50m.
Free cashflow (FCF) more than doubled to EUR 45m.
© SCHOTT Pharma
FY 2026 guidance confirmed
Revenue growth¹
EBITDA margin
$$
2\% - 5\%
$$
$$
\sim 27\%
$$
Additional information
CAPEX² of EUR 140 – 160m | HVS revenue share on prior year’s level
¹At constant currencies; ²Capex excluding leasing
© SCHOTT Pharma
SCHOTT PHARMA
Thank you for your attention
Investor Relations
[email protected]
[email protected]
Corporate Communications
[email protected]
[email protected]
© SCHOTT Pharma
Next financial events
| Aug 12, 2026: | Dec 10, 2026: | Feb 12, 2027: |
|---|---|---|
| 9M/Q3 2026 results | FY/Q4 2026 results | Q1 2027 results |
Next conference participations
| May 19, 2026: | May 27, 2026: | June 10, 2026: | Sep 22, 2026: |
|---|---|---|---|
| Berenberg | Deutsche Bank | Citi European | Bank of America |
| European | European Champions | Healthcare Leaders | Global Healthcare |
| Conference | Conference | Conference | Conference |
| New York | Frankfurt | London | London |